Sirtris Pharmaceuticals (SIRT) Chief Executive Officer to Ring the NASDAQ Stock Market Opening Bell


ADVISORY, Oct. 15, 2007 (PRIME NEWSWIRE) --



 What:
 Christoph Westphal, M.D., Ph.D., CEO and co-founder of Sirtris
 Pharmaceuticals, will preside over the opening bell. He will be
 joined by members of the Sirtris management team including Garen
 Bohlin, Chief Operating Officer, Peter Elliot, Ph.D., SVP
 Development, Michael Jirousek, Ph.D., SVP Research, Paul Brannelly,
 VP Finance, Michelle Dipp, M.D., Ph.D., Director of Corporate
 Development, and David Sinclair, Ph.D., co-founder and member of the
 Board of Directors of Sirtris.

 Where:
 NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio

 When:
 Tuesday, October 16, 2007 at 9:30 a.m. ET

 Contacts:
 Sheryl Seapy; 949-903-4750; sheryl@purecommunicationsinc.com

 NASDAQ MarketSite:
 Jolene Libretto; 646-441-5220; mobile - 347-219-9539;
 Jolene.Libretto@NASDAQ.com

Feed Information:

The opening bell is available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Jolene Libretto at (646) 441-5220.

Radio Feed:

An audio transmission of the opening bell is also available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band/ transponder 24, downlink frequency 4180 horizontal. The feed can be found on Waterfront fiber 1623 as well.

Webcast:

A live webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/reference/marketsite_about.stm.

Photos:

To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.

About Sirtris Pharmaceuticals (SIRT):

Headquartered in Cambridge, Massachusetts, Sirtris Pharmaceuticals (Nasdaq:SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. The company's drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of sirtuins, a recently discovered class of enzymes that control the aging process. More information about the company is available at www.sirtrispharma.com.